Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Free-Breathing MRI could make liver scans easier for kids

NCT ID NCT04591106

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested new MRI and MRE techniques that let children breathe normally during scans, instead of holding their breath. The goal was to measure liver fat and stiffness more comfortably and accurately in kids with fatty liver disease. 135 children aged 6-17 took part, and the new method was compared to standard breath-hold scans and liver biopsies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

135 people

The number who actually took part.

Started

Feb 2021

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study 1 (Aim 1 and Aim 2): 50 healthy subjects 6-17 years old, 50 subjects with NAFLD 6-17 years old; Study 2 (Aim 3): 60 subjects with Liver Disease and Fibrosis 1 month-40 years old; Study 3 (Aim 4): Study 3 (Aim 4): 15 Pairs of Healthy Infants (1 week-6 months old) and their Mothers. 15 Pairs of Infants (1 week-6 months old) born to Mothers with Gestational Diabetes and their Mothers.

Ages

1 week to 40 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion and Exclusion Criteria Study 1 (Aim 1 and Aim 2): Inclusion criteria for the NAFLD cohort: * 6-17 years of age * BMI \>85th percentile * diagnosed or clinically suspected to have NAFLD (NAFLD or suspected NAFLD is defined as serum alanine transaminase concentration \>30 IU/L in the appropriate clinical setting) * ability to follow instructions and perform short breath holds Inclusion criteria for the healthy cohort: * 6-17 years of age * body mass index \<85th percentile * ability to follow instructions and perform short breath holds Exclusion criteria for both cohorts: * known liver disease (except for NAFLD/NASH for the NAFLD cohort) * congenital malformation * inborn error of metabolism * contraindications to MRI * inability to perform breath-holding Study 2 (Aim 3): Inclusion criteria: * children and adults 1 month-40 years of age * liver disease and suspected or confirmed fibrosis * clinically ordered liver biopsy * Liver diseases include NAFLD/NASH, viral/medication induced hepatitis, autoimmune sclerosing cholangitis, intestinal failure associated liver disease, idiopathic hepatitis, Wilson's disease, hemosiderosis, liver rejection, and metabolic/genetic disorders * A liver biopsy must be planned/anticipated, performed, or scheduled to be performed within ±6 months of the MRI/MRE for this study Exclusion Criteria: * contra-indications to MRI/MRE * inability to perform breath-holding Study 3 (Aim 4): Inclusion criteria for the cohort of infants at risk for future obesity and NAFLD: * 1 week-6 months of age * greater than or equal to 35 weeks gestational age * born to a mother with gestational diabetes and whose pre-pregnancy body mass index \>=25 kg/m2 * mother must provide consent to participate in the study Inclusion criteria for the healthy cohort: * 1 week-6 months of age * greater than or equal to 35 weeks gestational age * appropriate for gestational age birth weight * born to a mother with a pre-pregnancy body mass index \<25 kg/m2 and without any major co-morbid conditions (gestational diabetes, pregnancy-induced hypertension, etc.) * admitted to the newborn nursery after birth * mother must provide consent to participate in the study Exclusion criteria for both cohorts: * known liver disease and/or infection, major congenital anomalies, inborn error of metabolism * any contraindications for an MRI exam

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune sclerosing cholangitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • UCLA Medical Center

    Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.